Eliquis
The latest news about Eliquis: headlines, AI summaries and the full story from every source.
- Morgan Stanley Maintains Underweight Rating on Bristol Myers Squibb Despite Strong Q2 Results
- Pfizer Exceeds Earnings and Revenue Estimates, Reaffirms 2026 Outlook
- Eliquis Faces Major Revenue Decline Due to Patent Expiry
- Bristol Myers Squibb Reports Strong First-Quarter Sales Growth, Primarily from Legacy Products